Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > The phase 1a trial has already been de-risked

<< Previous

Bullboard Posts

Next >>

Comment by CreatingApeon Jan 31, 2022 10:42pm

177 Views

Post# 34383071

RE:The phase 1a trial has already been de-risked

What about the 7 mil shares traded and the 40 % jump (that scaled back completely) on the day when the data on mice was released. People are aware but no one else is reading the tea leaves as closely as we are. When the human data is released, if it shows efficacy and safety at a high dose.. we are going to see another 10 mil shares traded and a serious bump in valuation.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec